ILMN

Business Context and Reporting Period

Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 28, 2009 (Three and Six Months)
Business Overview: Illumina is a leading developer of integrated systems for large-scale genetic analysis, serving sequencing, genotyping, and gene expression markets. The company operates primarily in one segment, with a Life Sciences Business Unit and an emerging Diagnostics Business Unit.

Key Financial Metrics

Note: Operating cash flow is reported for the six-month period only. Debt is primarily convertible senior notes.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 15% year-over-year for the quarter and 25% for the six-month period. Product revenue grew 19% (quarter) and 29% (six months), driven by strong demand for Genome Analyzer systems and sequencing consumables.
• Profitability: Net income more than doubled for the quarter (95% increase) and nearly doubled for the six-month period (86% increase). Operating margins improved significantly, with income from operations rising from 17% to 23% of revenue for the quarter.
• Expense Increases: Research and Development (R&D) expenses increased 41% for the quarter and 49% for the six months, driven by headcount growth and spending on sequencing and BeadArray technologies. Selling, General, and Administrative (SG&A) expenses rose 18% and 22%, respectively, due to personnel costs.
• Cost of Revenue: Cost of product revenue as a percentage of revenue decreased from 38% to 30% (quarter) and 39% to 32% (six months), attributed to improved overhead absorption and lower material costs.

Guidance, Outlook, and Risks

• Outlook: Management expects strong demand for next-generation sequencing to continue. They anticipate R&D and SG&A expenses will increase in absolute dollars to support business expansion and product development.
• Liquidity: The company holds $790.3 million in cash, cash equivalents, and investments as of June 28, 2009. Management believes current resources are sufficient to fund operations for at least the next 12 months.
• Convertible Notes: $400 million in 0.625% Convertible Senior Notes due 2014 are convertible into cash and/or stock during specific windows. The notes were convertible from April 1, 2009, through September 30, 2009.
• Auction Rate Securities: The company holds $55.8 million in illiquid auction rate securities. A settlement with UBS allows the company to sell these at par value between June 2010 and July 2012. The fair value of these securities is subject to volatility.
• Risk Factors: Potential delays in customer purchases due to uncertainty surrounding the American Recovery and Reinvestment Act (stimulus funding). Continued price competition and the need for significant R&D investment are also noted risks.

Key Facts for Investor Verification

• Accounting Change: Verify the impact of the retroactive adoption of FSP APB 14-1 on convertible debt, which increased interest expense and reduced net income in prior periods for comparability.
• Debt Conversion: Monitor the conversion activity of the $400 million Convertible Senior Notes, which are currently convertible, potentially leading to equity dilution or cash outflows.
• Investment Liquidity: Assess the risk associated with the $55.8 million in auction rate securities and the reliance on the UBS settlement agreement for liquidity.
• R&D Spend: Confirm that the significant increase in R&D expenses (up 49% YoY for six months) aligns with expected product launches and technological advancements.
• Customer Concentration: Review the impact of government grant funding (e.g., NIH stimulus) on revenue stability, as delays in funding could cause customers to defer purchases.